Skip to main content
. 2015 Nov 1;31(11):1098–1108. doi: 10.1089/aid.2015.0098

FIG. 1.

FIG. 1.

CHARM-02 study flowchart. Pharmacokinetic (PK) analysis included eight participants who maintained study eligibility, received all three study products, and completed all three sampling periods. The safety analysis included all nine research participants enrolled regardless of eligibility throughout the study.